CARsgen Therapeutics (HKG:2171) presented the updated results of three drugs at the 66th Annual Congress of the American Society of Hematology, a Tuesday bourse filing said.
Two of the drugs, CT0590 and CT071, are currently being tested for the treatment of relapsed/refractory multiple myeloma, while Zevorcabtagene autoleucel has been approved for the same purpose by China's National Medical Products Administration.